Induction from methadone to sublingual buprenorphine: A descriptive clinical trial in a methadone patients sample treated in therapeutic communities;Inducción a buprenorfina sublingual desde metadona: Estudio clínico descriptivo en una muestra de pacientes tratados en una comunidad terapéutica

Trastornos Adictivos

Volumn 10, Issue 1, 2008, Pages 49-64

  Gonzalez Saiz F ^a   Gutierrez Ortega J ^a   Bilbao Acedos, I ^a   Ballesta Gomez R ^a   Lozano Rojas, O ^a  

^a Fundacion Andaluza para la Atencion a Las Drogodependencias e Incorporacion Social   (Spain)

Author keywords

Addiction; Buprenorphine; Opiate withdrawal; Therapeutic community

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; CLONIDINE; METHADONE;

ADULT; ANALYTIC METHOD; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG SUBSTITUTION; FEMALE; HOSPITAL ADMISSION; HUMAN; INFORMED CONSENT; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPIATE ADDICTION; PROSPECTIVE STUDY; RATING SCALE; WITHDRAWAL SYNDROME;

EID: 41649094370     PISSN: 15750973     EISSN: 15782638     Source Type: Journal    
DOI: 10.1016/S1575-0973(08)74546-X     Document Type: Article

References (36)

1. Ward J, Mattick RP, Hall W. Methadone maintenance treatment and other replacement therapies. Amsterdam: Harwood Academic Press; 1998.
2. Capone CT, López Haggerty EL, Acer K, Melchionda R, Holley E, Adams H, Logan F. Client variables associated with selection and outcome in a methadone tapering program. Int J Addict. 1994;29:387-94.
3. Maddux JF, Prihoda TJ, Vogtsberger KN. The relationship of methadone dose and other variables to outcomes of methadone maintenance. Am J Addict. 1997;6;246-55.
4. Nwakeze PC, Magura S, Demsky S. Patient and program effects on retention in methadone treatment: A preliminary report. J Maint Addict. 1997;1;63-74.
5. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Useful predictors of outcome in methadone-treatment patients: Results from a controlled clinical trial with three dose of methadone. J Maint Addict. 1998;1;15-28.
6. Maremmani I, Pacini M, Lubrano S, Lovrecic M. When «enough» is still not «enough». Effectiveness of high-dose methadone in the treatment of heroin addiction. Heroin Add & Rel Clin Probl. 2003;5;17-32.
7. McLellan AT, Alterman AI. Patient treatment matching: a conceptual and methodological review with suggestions for future research. En: Pickens RW, Leukefeld CG, Schuster CR, editors. Improving drug abuse treatment. National Institute on Drug Abuse Monograph Series No. 106. 1991.
8. Strain EC. High-dose buprenorphine for treatment of opioid dependence. En: Kintz P, Market P, editors. Buprenorphine therapy of opioid addiction. New Jersey: Humana Press. 2002; 29-49.
9. Ling W, Wesson DR. Clinical efficacy of buprenorphine: comparisons to methadone and placebo, Drug Alcohol Depend. 2003;70;49-57.
10. Roncero C, Casas M. Eficacia clínica de la buprenorfina. Trastornos Adictivos. 2005;7;23-6.
11. Pérez de los Cobos J, Martin S, Etcheberrigaray A, Trujols J, Batlle F, Tejero A, et al. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence. Drug Alcohol Depend. 2005;59;223-33.
12. Baño R. Tratamiento de sustitución con buprenorfina (Subutex®): modelo de aplicación de una experiencia piloto en la Comunidad de Madrid. Trastornos Adictivos. 2003;5;303-8.
13. Barnett PG, Rodgers JH, Bloch A. A meta-analysis comparing buprenorphine to methadone for treatment of opiate dependence. Addiction. 2001;96:683-90.
14. Lintzeris N. Induction and tranfer. Ponencia en la Reunión Científica «Safer Options in the Treatment of Opioid Dependence». Rome, 2004.
15. Breen CL, Harris SJ, Lintzeris N, Mattick RP, Hawken L, Bell J, et al. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depend. 2003;71;49-55.
16. Lintzeris N, Clark N, Muhleisen P, Ritter A, Ali R, Bell J, et al. Clinical guidelines: buprenorphine treatment of heroin dependence. National Expert Advisory Committee on Illicit Drugs (NEACID) Canberra: Commonwealth of Australia; 2001.
17. Walsh SL, Eissenberg T. The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend. 2003;70;S13-27.
18. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it. Drug Alcohol Depend. 2003;70;S59-77.
19. Zweben JE, Aly T, Martin J, Wengrofsky S, Bacci J, Meddaugh R. Making residential treatment available to methadone clients, J Subst Abuse Treat. 1999;17;249-56.
20. Broekaert E, Vandevelde S, Soyez V, Yates R, Slater A. The third generation of therapeutic communities: the early development of the TC for addictions in Europe. Eur Addict Res. 2006;12;1-11.
21. Collins ED, Horton T, Reinke K, Amass L, Nunes EV. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation, J Subst Abuse Treat. 2007;32;167-75.
22. González-Saiz F, Ballesta Gómez R, Bilbao Acedos I, Lozano Rojas O, Gutiérrez Ortega J. Transfer from methadone to buprenorphine in residential therapeutic communities: an addiction-related quality of life assessment, Her Addict & Rel Clin Probl. En prensa 2008.
23. Handelsman L, Cochrane K, Marvin M, Ness R, Rubinstein K, Kanof P. Two new rating scales for opiate withdrawal. Am J Drug Alc Abuse. 1987;13;293-308.
24. Comisionado para las Drogodependencias. Catálogo de Servicios Asistenciales de los Centros de Tratamiento Ambulatorio de Andalucía. Consejería de Asuntos Sociales. Junta de Andalucía. 2003.
25. Lozano Rojas O. Construcción de un test para medir la calidad de vida relacionada con la salud. Tesis Doctoral. Universidad de Granada. 2005.
26. Edwards G, Gross M. Alcohol dependence: provisional description of a clinical síndrome. Brit Med J. 1976;1;1058-61.
27. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multidimensional instrument for assessing outcomes of treatment among opiate users. British J Addict. 1992;87;733-42.
28. González-Saiz F. Estandarización de un instrumento de evaluación en los trastornos adictivos. Tesis Doctoral. Universidad de Cádiz. 1997.
29. Goldberg G, Hillier VF. A scaled version of the General Health Questionnaire, Psychol Med. 1979;9;139-45.
30. Wing JK, Babor T, Brugha T, Burke J, Cooper JE, Giel R, et al. SCAN: Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psych. 1990;47;589-93.
31. Huestis M. Controlled drug administration studies of high-dose buprenorphine in humans. En: Kintz P, Market P. Buprenorphine therapy of opioid addiction. New Jersey: Humana Press; 2002; 13-27.
32. McNicholas L. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Center for Substance Abuse Treatment. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2004.
33. Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rössler H, Hinterhuber H. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98;693-702.
34. Giacomuzzi SM, Ertl M, Kemmler G, Riemer Y, Vigl A. Sublingual buprenorphine and methadone maintenance treatment: a three-year followup of quality of life assessment. Scient World J. 2005;5:452-68.
35. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349;949-58.
36. González-Saiz F, Lozano Rojas O, Ballesta Gómez R, Bilbao Acedos I, Galiana Martínez J, García Collantes MA, et al and Serm Methadone Levels Study Group. Evidence of reliability and validity of the Opiate Dosage Adequacy Scale (O.D.A.S.) in a sample of methadone maintenance patients. Her Addict Rel Clin Probl. En prensa 2008.